Advanced search
1 file | 5.04 MB Add to list

Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model

Félix Gremonprez (UGent) , Benedicte Descamps (UGent) , Andrei Izmer (UGent) , Christian Vanhove (UGent) , Frank Vanhaecke (UGent) , Olivier De Wever (UGent) and Wim Ceelen (UGent)
(2015) ONCOTARGET. 6(30). p.29889-29900
Author
Organization
Abstract
Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer. However, especially after incomplete cytoreduction, disease progression is common and this is likely due to limited tissue penetration and efficacy of intraperitoneal cytotoxic drugs. Tumor microenvironment-targeting drugs, such as VEGF(R) and PDGFR inhibitors, can lower the heightened interstitial fluid pressure in tumors, a barrier to drug delivery. Here, we investigated whether tumor microenvironment-targeting drugs enhance the effectiveness of intraperitoneal chemotherapy. A mouse xenograft model with two large peritoneal implants of colorectal cancer cells was developed to study drug distribution and tumor physiology during intraperitoneal Oxaliplatin perfusion. Mice were treated for six days with either Placebo, Imatinib (anti-PDGFR, daily), Bevacizumab (anti-VEGF, twice) or Pazopanib (anti-PDGFR, -VEGFR; daily) followed by intraperitoneal oxaliplatin chemotherapy. Bevacizumab and Pazopanib significantly lowered interstitial fluid pressure, increased Oxaliplatin penetration (assessed by laser ablation inductively coupled plasma mass spectrometry) and delayed tumor growth of peritoneal implants (assessed by MRI). Our findings suggest that VEGF(R)-inhibition may improve the efficacy of IPC, particularly for patients for whom a complete cytoreduction might not be feasible.
Keywords
peritoneal carcinomatosis, colorectal cancer, angiogenesis, oxaliplatin, PERITONEAL CARCINOMATOSIS, SYSTEMIC CHEMOTHERAPY, CYTOREDUCTIVE SURGERY, RANDOMIZED-TRIAL, LUNG-CANCER, BEVACIZUMAB, THERAPY, MICROENVIRONMENT, OXALIPLATIN, NORMALIZATION

Downloads

  • OncoTarget Gremonprez Pretreatment with VEGF R -inhibitors prior to HIPEC 2015.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 5.04 MB

Citation

Please use this url to cite or link to this publication:

MLA
Gremonprez, Félix et al. “Pretreatment with VEGF(R)-inhibitors Reduces Interstitial Fluid Pressure, Increases Intraperitoneal Chemotherapy Drug Penetration, and Impedes Tumor Growth in a Mouse Colorectal Carcinomatosis Model.” ONCOTARGET 6.30 (2015): 29889–29900. Print.
APA
Gremonprez, F., Descamps, B., Izmer, A., Vanhove, C., Vanhaecke, F., De Wever, O., & Ceelen, W. (2015). Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model. ONCOTARGET, 6(30), 29889–29900.
Chicago author-date
Gremonprez, Félix, Benedicte Descamps, Andrei Izmer, Christian Vanhove, Frank Vanhaecke, Olivier De Wever, and Wim Ceelen. 2015. “Pretreatment with VEGF(R)-inhibitors Reduces Interstitial Fluid Pressure, Increases Intraperitoneal Chemotherapy Drug Penetration, and Impedes Tumor Growth in a Mouse Colorectal Carcinomatosis Model.” Oncotarget 6 (30): 29889–29900.
Chicago author-date (all authors)
Gremonprez, Félix, Benedicte Descamps, Andrei Izmer, Christian Vanhove, Frank Vanhaecke, Olivier De Wever, and Wim Ceelen. 2015. “Pretreatment with VEGF(R)-inhibitors Reduces Interstitial Fluid Pressure, Increases Intraperitoneal Chemotherapy Drug Penetration, and Impedes Tumor Growth in a Mouse Colorectal Carcinomatosis Model.” Oncotarget 6 (30): 29889–29900.
Vancouver
1.
Gremonprez F, Descamps B, Izmer A, Vanhove C, Vanhaecke F, De Wever O, et al. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model. ONCOTARGET. 2015;6(30):29889–900.
IEEE
[1]
F. Gremonprez et al., “Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model,” ONCOTARGET, vol. 6, no. 30, pp. 29889–29900, 2015.
@article{6985859,
  abstract     = {Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer. However, especially after incomplete cytoreduction, disease progression is common and this is likely due to limited tissue penetration and efficacy of intraperitoneal cytotoxic drugs. Tumor microenvironment-targeting drugs, such as VEGF(R) and PDGFR inhibitors, can lower the heightened interstitial fluid pressure in tumors, a barrier to drug delivery. Here, we investigated whether tumor microenvironment-targeting drugs enhance the effectiveness of intraperitoneal chemotherapy. A mouse xenograft model with two large peritoneal implants of colorectal cancer cells was developed to study drug distribution and tumor physiology during intraperitoneal Oxaliplatin perfusion. Mice were treated for six days with either Placebo, Imatinib (anti-PDGFR, daily), Bevacizumab (anti-VEGF, twice) or Pazopanib (anti-PDGFR, -VEGFR; daily) followed by intraperitoneal oxaliplatin chemotherapy. Bevacizumab and Pazopanib significantly lowered interstitial fluid pressure, increased Oxaliplatin penetration (assessed by laser ablation inductively coupled plasma mass spectrometry) and delayed tumor growth of peritoneal implants (assessed by MRI). Our findings suggest that VEGF(R)-inhibition may improve the efficacy of IPC, particularly for patients for whom a complete cytoreduction might not be feasible.},
  author       = {Gremonprez, Félix and Descamps, Benedicte and Izmer, Andrei and Vanhove, Christian and Vanhaecke, Frank and De Wever, Olivier and Ceelen, Wim},
  issn         = {1949-2553},
  journal      = {ONCOTARGET},
  keywords     = {peritoneal carcinomatosis,colorectal cancer,angiogenesis,oxaliplatin,PERITONEAL CARCINOMATOSIS,SYSTEMIC CHEMOTHERAPY,CYTOREDUCTIVE SURGERY,RANDOMIZED-TRIAL,LUNG-CANCER,BEVACIZUMAB,THERAPY,MICROENVIRONMENT,OXALIPLATIN,NORMALIZATION},
  language     = {eng},
  number       = {30},
  pages        = {29889--29900},
  title        = {Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model},
  url          = {http://dx.doi.org/10.18632/oncotarget.5092},
  volume       = {6},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: